The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

The genetic testing company 23andMe is poised to be sold to a nonprofit run by the company's former chief executive Anne ...

Anne Wojcicki has been declared the winner of a bankruptcy auction for 23andMe, the genetics testing start-up she founded, ...

A nonprofit led by Anne Wojcicki, the co-founder and former chief executive of 23andMe, won a bid to acquire the genetic testing company following its bankruptcy filing in ...

Several states have joined a lawsuit against 23andme. They say bankruptcy shouldn't allow the genetic testing company to sell ...

Anne Wojcicki's nonprofit is set to purchase all significant assets of the bankrupt genetic testing company, 23andMe, for ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

Anne Wojcicki, the co-founder and former CEO of 23andMe, will purchase the bankrupt company’s assets for $305 million, the genetic testing company said Friday. Regeneron Pharmaceuticals had agreed to ...

Me, which became a household name for its genetic testing services, is set to emerge from bankruptcy as a nonprofit.

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed ...